Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

Shots:

  • The P-III VARSITY study results involves assessing of Entyvio (vedolizumab,IV) vs Humira (adalimumab,SC) in 769 patients with moderate to severely active ulcerative colitis for 52wks.
  • The P-III VARSITY study results: @52wks. clinical remission (31.3% vs 22.5%); mucosal healing (39.7% vs 27.7%); AEs (62.7% vs 69.2%); rate of infection (33.5% vs 43.5%); SAEs (11.0% vs. 13.7%) @14wks. greater clinical response than adalimumab
  • Entyvio (vedolizumab, IV) is a gut-selective biologic targeting alpha4beta7 integrin, inhibiting its binding with MAdCAM-1, indicated to treat UC & CD. Humira (adalimumab) is an anti-TNF drug, is indicated as monothx. or in combination with methotrexate for RA, psoriatic arthritis, ankylosing spondylitis

Click here to read full press release/ article | Ref: Takeda| Image: Booth Design Ideas